Article · Wikipedia archive · Last revised Jun 12, 2026

2CJP

2CJP, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2-benzazepine, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families. It is a cyclized phenethylamine analogue of 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydrobenzazepine ring. The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors. 2CJP was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.

Last revised
Jun 12, 2026
Read time
≈ 1 min
Length
249 w
Citations
10
Source
Wikipedia ↗
2CJP
Clinical data
ATC code
  • None
Identifiers
  • 4-(4-bromo-2,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2-benzazepine
Chemical and physical data
FormulaC18H20BrNO2
Molar mass362.267 g·mol−1
3D model (JSmol)
  • COc1cc(Br)c(cc1C1CNCc2c(C1)cccc2)OC
  • InChI=1S/C18H20BrNO2/c1-21-17-9-16(19)18(22-2)8-15(17)14-7-12-5-3-4-6-13(12)10-20-11-14/h3-6,8-9,14,20H,7,10-11H2,1-2H3
  • Key:FQAXYSXGRJQKMV-UHFFFAOYSA-N

2CJP, also known as 4-(4-bromo-2,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2-benzazepine, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families.1234 It is a cyclized phenethylamine analogue of 25B-NBOMe in which the N-benzylethylamine side chain has been cyclized to form a tetrahydrobenzazepine ring.12 The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 19–457 nM and 227–3,240 nM, respectively).34 2CJP was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.12

See also

See also

References

References

  1. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 837–840, 866–867. ISBN 978-3-03788-700-4. OCLC 858805226.
  2. Braden MR (2007). Towards a Biophysical Understanding of Hallucinogen Action (Ph.D. thesis). Purdue University. ProQuest 304838368. Archived from the original on 2025-01-21. Retrieved 2025-08-01.
  3. Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
  4. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC 3547484. PMID 23336049.
External links